Argos Therapeutics (ARGS) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Stifel Cuts Price target on Argos Therapeutics (ARGS) Following 4Q15 Results
March 30, 2016 9:19 AM EDTStifel maintained a Buy rating on Argos Therapeutics (NASDAQ: ARGS), and cut the price target to $10.00 (from $16.00), following the company's 4Q earnings report. ARGS reported an EPS loss of ($0.84), and a cash position of $7.2M.
Analyst Thomas Shrader commented, "Argos reported 4Q15... More
